Literature DB >> 2258703

Effects of interferon alpha on autocrine growth factor loops in B lymphoproliferative disorders.

H E Heslop1, A C Bianchi, F T Cordingley, M Turner, W Chandima, C P De Mel, A V Hoffbrand, M K Brenner.   

Abstract

The B lymphoproliferative disorders B chronic lymphocytic leukemia (B-CLL) and hairy cell leukemia (HCL) produce a number of autocrine growth factors, including tumor necrosis factor (TNF), interleukin 6 (IL-6), and IL-1, all of which may induce positive feedback growth loops. If such malignancies depend on these autocrine growth loops for survival, their interruption may be therapeutically valuable. Interferon alpha (IFN-alpha) abrogates TNF- or IL-6-induced proliferation of HCL and B-CLL cells in vitro and has therapeutic activity in these diseases. We have investigated the possibility that IFN-alpha may act by interrupting autocrine growth factor loops. If purified B-CLL or HCL cells are cultured in the presence of TNF, there is induction of mRNA for TNF, IL-1 alpha, IL-1 beta, and IL-6. However, culture in the presence of IFN-alpha in addition to TNF reduced the level of mRNA for all these cytokines, compared with cells cultured in TNF alone. While cytokine mRNA levels were diminished, levels of mRNA for the ribonuclease activator 2-5A synthetase were increased. Analysis of the kinetics of cytokine mRNA production showed that levels fall shortly after the rise of 2-5A synthetase mRNA. IFN-alpha may produce these effects by shortening the half-life of cytokine mRNA, since TNF mRNA half-life in B-CLL and HCL cells is substantially reduced when the cells are cultured with IFN-alpha. These data suggest that IFN-alpha may mediate its therapeutic effects in these malignancies by blocking autocrine growth factor loops.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2258703      PMCID: PMC2188757          DOI: 10.1084/jem.172.6.1729

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  19 in total

1.  Proliferative response of hairy cells to B cell growth factor (BCGF): in vivo inhibition by interferon-alpha and in vitro effects of interferon-alpha, -beta, and -gamma.

Authors:  E Genot; C Billard; F Sigaux; C Mathiot; L Degos; E Falcoff; J P Kolb
Journal:  Leukemia       Date:  1987-08       Impact factor: 11.528

2.  Proposals for the classification of chronic (mature) B and T lymphoid leukaemias. French-American-British (FAB) Cooperative Group.

Authors:  J M Bennett; D Catovsky; M T Daniel; G Flandrin; D A Galton; H R Gralnick; C Sultan
Journal:  J Clin Pathol       Date:  1989-06       Impact factor: 3.411

3.  A conserved AU sequence from the 3' untranslated region of GM-CSF mRNA mediates selective mRNA degradation.

Authors:  G Shaw; R Kamen
Journal:  Cell       Date:  1986-08-29       Impact factor: 41.582

Review 4.  Biochemistry of interferons and their actions.

Authors:  P Lengyel
Journal:  Annu Rev Biochem       Date:  1982       Impact factor: 23.643

Review 5.  Alpha interferon in the treatment of hematologic malignancies.

Authors:  M S Roth; K A Foon
Journal:  Am J Med       Date:  1986-11       Impact factor: 4.965

6.  Leukemia diagnosis and testing of complement-fixing antibodies for bone marrow purging in acute lymphoid leukemia.

Authors:  D Campana; G Janossy
Journal:  Blood       Date:  1986-12       Impact factor: 22.113

7.  The beneficial effects of alpha-interferon in hairy cell leukemia are not attributable to NK cell-mediated cytotoxicity.

Authors:  S D Griffiths; J C Cawley
Journal:  Leukemia       Date:  1987-04       Impact factor: 11.528

8.  B cell growth factor-induced proliferation of hairy cell lymphocytes and inhibition by type I interferon in vitro.

Authors:  K A Paganelli; S S Evans; T Han; H Ozer
Journal:  Blood       Date:  1986-04       Impact factor: 22.113

9.  Identification of a common nucleotide sequence in the 3'-untranslated region of mRNA molecules specifying inflammatory mediators.

Authors:  D Caput; B Beutler; K Hartog; R Thayer; S Brown-Shimer; A Cerami
Journal:  Proc Natl Acad Sci U S A       Date:  1986-03       Impact factor: 11.205

10.  Stimulation of B-chronic lymphocytic leukemia populations by recombinant interleukin-4 and other defined growth-promoting agents.

Authors:  A A Ghaderi; P Richardson; C Cardona; M J Millsum; N Ling; S Gillis; J Ledbetter; J Gordon
Journal:  Leukemia       Date:  1988-03       Impact factor: 11.528

View more
  14 in total

Review 1.  Medical approaches and future options in chronic active ulcerative colitis.

Authors:  J T Siveke; C Folwaczny
Journal:  Int J Colorectal Dis       Date:  2004-01-15       Impact factor: 2.571

Review 2.  Antibody-cytokine fusion proteins for treatment of cancer: engineering cytokines for improved efficacy and safety.

Authors:  Patricia A Young; Sherie L Morrison; John M Timmerman
Journal:  Semin Oncol       Date:  2014-08-12       Impact factor: 4.929

3.  Diminished production of monocyte proinflammatory cytokines during human immunodeficiency virus viremia is mediated by type I interferons.

Authors:  John C Tilton; Alison J Johnson; Marlise R Luskin; Maura M Manion; Jun Yang; Joseph W Adelsberger; Richard A Lempicki; Claire W Hallahan; Mary McLaughlin; Joann M Mican; Julia A Metcalf; Christiana Iyasere; Mark Connors
Journal:  J Virol       Date:  2006-09-27       Impact factor: 5.103

4.  Differential human multiple myeloma cell line responsiveness to interferon-alpha. Analysis of transcription factor activation and interleukin 6 receptor expression.

Authors:  D F Jelinek; K M Aagaard-Tillery; B K Arendt; T Arora; R C Tschumper; J J Westendorf
Journal:  J Clin Invest       Date:  1997-02-01       Impact factor: 14.808

5.  Interferon-alpha activates cytotoxic function but inhibits interleukin-2-mediated proliferation and tumor necrosis factor-alpha secretion by immature human natural killer cells.

Authors:  A Jewett; B Bonavida
Journal:  J Clin Immunol       Date:  1995-01       Impact factor: 8.317

6.  Morphologic and immunophenotypic characterization of a cell line derived from liver tissue with Epstein-Barr virus associated post-transplant lymphoproliferative disease.

Authors:  P S Randhawa; A Zeevi; C Alvares; S Gollin; R Agostini; E Yunis; S Saidman; L Contis; A J Demetris; M A Nalesnik
Journal:  In Vitro Cell Dev Biol Anim       Date:  1994-06       Impact factor: 2.416

7.  Interleukin-6 functions as an intracellular growth factor in hairy cell leukemia in vitro.

Authors:  B Barut; D Chauhan; H Uchiyama; K C Anderson
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

8.  Control of human B cell tumor growth in severe combined immunodeficiency mice by monoclonal anti-B cell antibodies.

Authors:  A Durandy; N Brousse; F Rozenberg; G De Saint Basile; A M Fischer; A Fischer
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

9.  Prospective evaluation of interferon-alpha in treatment of chronic active Crohn's disease.

Authors:  C Gasché; W Reinisch; H Vogelsang; R Pötzi; E Markis; M Micksche; H P Wirth; A Gangl; H Lochs
Journal:  Dig Dis Sci       Date:  1995-04       Impact factor: 3.199

10.  Disruption by interferon-alpha of an autocrine interleukin-6 growth loop in IL-6-dependent U266 myeloma cells by homologous and heterologous down-regulation of the IL-6 receptor alpha- and beta-chains.

Authors:  M Schwabe; A T Brini; M C Bosco; F Rubboli; M Egawa; J Zhao; G L Princler; H F Kung
Journal:  J Clin Invest       Date:  1994-12       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.